Loading clinical trials...

Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma

Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma. Efficacy of Seocalcitol (EB 1089) Enteric-Coated Capsules (5 ug) or Placebo in Prolonging Time to Relapse Following Intended Curative Resection or Percutaneous Ablative Treatment for Hepatocellular Carcinoma

NCT00051545•LEO Pharma

View on ClinicalTrials.gov

Summary

To evaluate the efficacy of Seocalcitol in prolonging time to relapse following intended curative resection or percutaneous ablative treatment, i.e. percutaneous ethanol injection(s), percutaneous acetic acid injection(s), percutaneous microwave coagulation therapy, or percutaneous radiofrequency ablation for hepatocellular carcinoma (HCC).

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Hospital in- or out patients
•Either sex
•18 to 75 years of age
•With hepatocellular carcinoma treated successfully with surgical resection or percutaneous ablative treatment within 4 and 8 weeks, respectively, prior to inclusion.
•All patients must give their signed informed consent to join the study.

Exclusion Criteria

•Patients previously treated with any anti-cancer therapy for HCC except for surgical resection and percutaneous ablative therapy
•Patients treated with chemotherapy or other anti-cancer therapy (except surgical resection or percutaneous ablative treatment) in the previous 4 weeks
•Patients with another primary tumor except basocellular carcinoma of the skin or in situ carcinoma of the cervix within the last 2 years
•With a history of renal stone(s)
•With a life expectancy \< 3 months
•WHO performance status 3 or 4.
•Patients with hypercalcemia (ionised serum calcium \> 1.35 mmol/l or albumin corrected serum calcium \> 2.68 mmol/l), previous/current calcium metabolic disease, taking calcium-lowering therapy or medication known to affect systemic calcium metabolism, or with marked laboratory abnormalities.
•Patients with recurrent hepatocellular carcinoma, with known extrahepatic metastases, Okuda stage III disease and patients with a Child-Pugh score of C are also excluded.

Locations (5)

E.g., University Health Network Toronto General Hospital (numerous facilities in Canada are recruiting)

Toronto, Ontario, Canada

E.g., Hopital Notre-Dame de Bon Secour, Service de Hepato-gastro-enterologie (numerous facilities are recruiting in France)

Metz, France

E.g., Osp. Maggiore, Policlinico di Milano, Divisione di Medicina Interna (numerous facilities are recruiting in Italy)

Milan, Italy

E.g. Hospital Clinic Provincial de Barcelona (numerous facilities are recruiting in Spain)

Barcelona, Spain

E.g., The University of Edinburgh Royal Infirmary (numerous facilities are recruiting in UK)

Edinburgh, United Kingdom

Key Dates

Start Date

November 1, 1999

Completion Date

June 1, 2004

Last Updated

February 25, 2025

Enrollment

608

Estimated participants

Conditions

Liver Neoplasms

Interventions

Seocalcitol

DRUG

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

NCT07225114

Breast CancerKidney Neoplasms+1 more

View study

COMPLETEDNA

Biliary Anastomosis Using Surgical Loupe Versus Microscope in Living Donor Liver Transplantation

NCT04618692

Liver FailureLiver Diseases+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Seocalcitol Versus Placebo in the Adjuvant Treatment of Hepatocellular Carcinoma

Inclusion Criteria

Exclusion Criteria

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

Biliary Anastomosis Using Surgical Loupe Versus Microscope in Living Donor Liver Transplantation

TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC

Short Term Surgical Outcomes of Anatomical Versus Non Anatomical Laparoscopic Liver Resection for Liver Tumors

NAC to Prevent Cisplatin-induced Hearing Loss

A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants